Panel · Use case · Market Access

Net Price Erosion Range.

LiveEstimate Elicitation

By what percent will the net price fall over the first three years after launch, given payer and policy conditions?

QuantityPercent fall in net price over the first three years

SeatsAccess, evidence, HEOR, compliance

ReaderPricing and access leads

Not askedA price recommendation

DepthStandard, four seats

Net Price Erosion Range is a ready-made use case for Market Access. It ships under the Estimate Elicitation template.

For market access leads. You get each seat's low, central and high with its anchors, the pooled range and what it is not, and what would narrow it. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

By what percent will the net price fall over the first three years after launch, given payer and policy conditions?

Who estimates

Net price is the list price less rebates and discounts. Policy can shape it directly: in the United States, Medicare negotiates prices for selected drugs, and rebate practices are under study by the FTC.

Seat	What it estimates from	Why it is at the table
Global Market Access Director	Rebate levels needed for access and the effect of competition within a class.	Payer contracting patterns.
Global Value & Evidence Lead	How the evidence of benefit supports or weakens the price.	Clinical evidence.
HEOR Evidence Lead	How assessment bodies and payers reference value to price.	Value assessments.
Global Commercial Compliance Officer	Which pricing and rebate practices are constrained by law and policy.^{1Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program.,2U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024.}	The Medicare negotiation program and the FTC report.

What the elicitation does

Define net price. The quantity states what is netted out, the payer mix and the reference price. A fall in list price and a fall in net price are different things.^{2U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024.}

Policy is a driver. The Medicare drug price negotiation program applies to selected high-spend drugs after a number of years on the market. The report says whether the product is exposed within the three-year window.^{1Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program.}

Concentration of buyers. The FTC reported that three managers processed nearly 80 percent of prescriptions in 2023, which affects bargaining. The seats say how.^{2U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024.}

Recommended length

Standard

Four angles bear on the number. Standard depth gives each a seat, with the dossier and the reasons for the spread, in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the elicitation checks

The elicitation states the assumptions each estimate rests on, and says what each gap limits. Examples for this quantity:

The payer mix at launch is similar to the analogs.
No policy change alters rebate rules within three years.
Competing products enter the class on the expected timeline.

Standards, guidance and sources

Anchors

CMS, Medicare Drug Price Negotiation Program.^{1Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program.}
FTC, interim staff report on pharmacy benefit managers, July 2024.^{2U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any erosion figure taken from one analog, any estimate that mixes list and net price, and any assumption about policy that was not checked.

What arrives

The quantity and how it is judged
Evidence dossier
Seat judgments
Estimates side by side
Why the seats differ
Revised estimates after rebuttal
The pooled range and what it is not
What would narrow the range

What it will not do

The pool is a synthesis of AI judgments and not a calibrated distribution, and the seats are not weighted by performance. It does not narrow the range to look decisive.

It is not pricing advice and does not recommend a list price.

It is not a calibrated probability distribution. The pool is a synthesis of AI judgments, and the report says so.

It does not weight seats by performance. No calibration record exists for the AI seats.

It does not narrow the range to look decisive.

References

[1] Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program. Known from CMS’s site; not read in full.
[2] U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024. Figures as given in the FTC’s press release and search excerpts; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.